Trial Profile
An Open Non-Randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms XELTA
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record